Key result
Prior DOAC therapy in patients with atrial fibrillation and acute ischemic stroke was associated with a higher likelihood of favorable 3-month outcome compared to controls (aOR 1.24; 95% CI 1.01-1.51).
Why the study?
The study evaluated how prior anticoagulation with VKAs or DOACs associates with stroke severity, intravenous thrombolysis utilization and safety, and 3-month outcomes in patients with AF and acute ischemic stroke.
Does prior anticoagulation with VKAs or DOACs improve stroke severity and outcomes in patients with atrial fibrillation and acute ischemic stroke?
Cohort (n=8,179)
Does prior anticoagulation with VKAs or DOACs improve stroke severity and outcomes in patients with atrial fibrillation and acute ischemic stroke?
Odds Ratio: 1.24 (95% CI 1.01–1.51)
Prior DOAC therapy in patients with AF experiencing an acute ischemic stroke is associated with reduced stroke severity and better functional outcomes at 3 months, despite lower rates of intravenous thrombolysis.
No takes yet. Share an insight, caveat, or question.
May support DOAC use in eligible AF patients; extends observational data but leaves open randomized confirmation.
Meinel et al. (2020) conducted a cohort in Atrial fibrillation and acute ischemic stroke (n=8,179). Prior anticoagulation with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) vs. No anticoagulation (controls) was evaluated on Favorable outcome (modified Rankin Scale score 0-2) at 3 months (aOR 1.24, 95% CI 1.01-1.51). Prior DOAC therapy in patients with atrial fibrillation and acute ischemic stroke was associated with a higher likelihood of favorable 3-month outcome compared to controls (aOR 1.24; 95% CI 1.01-1.51).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: